Creative Biolabs specialists have identified that certain Enterococcus strains possess favorable qualities for use in Live Biotherapeutic Products due to their ability to tolerate bile salts and acidic environments, which facilitates gut colonization and increases their potential success as oral therapies. However, the opportunistic pathogen potential of Enterococcus presents a significant bottleneck in LBP development, particularly concerning virulence factors and growing multi-drug resistance issues like Vancomycin-Resistant Enterococcus.
The chief scientist of Creative Biolabs' LBP R&D department emphasized that safety assessment takes absolute priority when developing probiotic therapies using Enterococcus species. The evaluation process requires combining advanced genomics and in vitro toxicology with traditional microbial identification and functional screening techniques to assess both potential pathogenicity and probiotic effects simultaneously.
In response to these industry challenges, Creative Biolabs has established a tailored Enterococcus microbiome CRO service platform designed to provide customized, high-quality research services that move potential LBP candidates from discovery through preclinical evaluation stages. The platform includes precise screening and functional validation services that efficiently isolate and identify target strains from complex samples, followed by comprehensive functional and Mechanism of Action screening that considers metabolic capabilities, bacteriocin production, and anti-pathogen antagonism potential.
The most critical component of the research involves rigorous safety and resistance assessment, particularly for high-risk Enterococcus faecalis strains. Creative Biolabs offers complete biosafety and antimicrobial susceptibility testing packages that determine minimum inhibitory concentrations, test for transferable antibiotic resistance, and perform comprehensive biosafety evaluations. Additional services support host interaction studies and formulation optimization, including high-throughput host-microbe interaction testing, adhesion studies, gut barrier integrity testing with intestinal epithelial cell lines, and immune system modulation assessment.
The company's approach aims to transform effectively screened and safe Enterococcus strains into advanced therapeutic options that could provide new treatment avenues for complex conditions such as drug-resistant infections and inflammatory bowel disease. The specialized CRO services address the critical need for thorough safety evaluation in an area where regulatory requirements continue to evolve and become more stringent. This development matters because it addresses a fundamental safety paradox in microbiome therapeutics: harnessing potentially beneficial bacteria that also carry significant risks, particularly as antibiotic resistance becomes a global health crisis. The implications extend to regulatory frameworks, as demonstrating safety for such dual-nature microorganisms will set precedents for future LBP approvals. For patients with limited treatment options, particularly those with inflammatory bowel disease or antibiotic-resistant infections, this research could eventually lead to novel oral therapies that work through gut colonization mechanisms unavailable to traditional pharmaceuticals.
